drugset / Trial / NCT05167448
A Study of ES104 in Patients With Metastatic Colorectal Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal cancer who have failed systemic therapies.
Timeline
- Start
- 2022-02-25
- Primary completion
- 2026-05-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES104 | Unknown | 10 mg/kg | Intravenous |
| Subject | ES104 | Unknown | 12.5 mg/kg | Intravenous |